San Francisco, Ca., USA - March 16, 2015, San Francisco, Ca., USA - Achaogen, Inc., a clinical-stage biopharmaceutical company, announced the appointments of Alan Colowick and Kent Lieginger to its board of directors.
Article continues below
Dr. Colowick has held senior managerial positions at large and emerging biotechnology companies. Since 2010, Dr. Colowick has served in leadership roles at Celgene Corporation, where he most recently was President for the Europe, Mid-East, and Africa region from 2012 to 2014 and Senior Vice President Global Medical Affairs from 2010 to 2012.
Previously, Dr. Colowick was Chief Executive Officer of Gloucester Pharmaceuticals, LLC (sold to Celgene in 2010) and President, Oncology for Geron Corporation (2006-2008) where he was responsible for the strategic and operational activities of the company's oncology programs.
Earlier in his career, he held various management positions with Amgen Inc., including Vice President of European Medical Affairs, where he was responsible for products in multiple therapeutic areas, including hematology-oncology, nephrology and internal medicine.
Dr. Colowick has previously served as a clinical and research fellow in hematology and oncology at the Dana Farber Cancer Institute and Brigham and Women's Hospital at Harvard University. He holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University and an M.P.H from Harvard University.
Dr. Lieginger has most recently served as Senior Vice President, Managed Care and Customer Operations at Genentech, Inc., as well as Director of the Genentech Foundation since 2005. He originally joined Genentech as Vice President, Managed Care and Customer Operations in 2004 and served as a member of Genentech's Commercial Leadership Committee.
Prior to joining Genentech, Dr. Lieginger was Vice President, National Insurer and Employer Segment (Managed Markets Division) at GlaxoSmithKline plc, where he also led teams in U.S. and global business development, finance, strategic contracting, manufacturing, marketing, and sales.
He completed his residency in clinical pharmacy at the University of California in San Francisco, served for four years as Assistant Clinical Professor of Medicine at the University of California, Davis School of Medicine, and has served on the Board of Trustees at University of the Sciences in Philadelphia since 2013. ■